DPP4 inhibitor saxagliptin which increases the level of glucagon-like peptide-1 (GLP-1) and ameliorates T2DM, has become a valuable candidate as a disease-modifying agent in the treatment of AD. This evidence concerns the gene GCG and Alzheimer disease.